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Editorial Note
Reductionofinfarctsize:discrepanciesbetween
experimental work and clinical application
This issue of the Journal contains a convincing 
example-of pharmacological
reduction of infarct size after experimental coronary 
occlusion in rats [1]' chiariello
andcoworkershavedemonstratedthatd i lazep,ast imulantofcol la tera lc i rcu lat ion
may reduce infarct tir;;;;;toximately 20% as 
measured by enzyme depletion in
theacutephaseanduyu, ,nu"nas40voasmeasuredhisto logical lyaf ter3weeks.
A naive scientist may ask if patients in coronary 
wards will-now receive dilazep'
The clinician knows.t'u,.t '" u',*", is..no' '. He 
also knows that it may even take
yea rsbe fo rease r i ousc l i n i ca l t r i a l on thee f fec to fd i l azep inpa t i en t sw i thacu te
myocardial infarction will be started. There are 
seemingly good reasons for this
re luctanceinacceptanceofresul tsobta inedinanimalstudies. Infarcts ize inpat ients
w i thacu temyoca rd ia l i n fa rc t i onshowsa la rgeva r i a t i on . I t canbees t ima ted tha t
proofofa20voreduct ionofenzymereleaseaf teracutemyocardia l in farct ionwould
needatreatedu, ,du*nt .otg.o. ,pof l00pat ientseach,whichseemsimpract icable.
Another argument concerns the importance of infarct 
size as a clinical parametef'
For instance, in chiariello's study no significant 
difference in mortality was ob-
served. However, ,h"," utgu*ents are seemingly 
sound' A large number of studies
over the last l0 y"u., rru'rr" demonstrated tf,e 
retation between infarct size and
mortality or morbidity in patients with-acute myocardialii?:::l",-d 
the common
sense notion that a small infarction is better than 
a large one is a proven fact'
In my opinion' the poor follow-up of experimental 
work by clinical studies is
largely a question of trends' One of these present 
trends has been established by the
observat ionthat theborderzonebetweenheal thyandinfarctedmyocardiummaybe
quite narrow' suggesting only a small .quantity 
of salvageable tissue [2]' It is
surprising to find ttat ii.ect'proof to thl contiary, 
as also given in Chiariello's
study, is disregarded in thls,.bo.der zone" discussion. 
The importance of trends in
this field is also demonstrated by the recent interest 
in the intracoronary application
of streptokinur" urt". u"uie myocardial infarction. 
Streptokinase has been used for
yearsandhasbeenprovenbenef ic ia l inh igh-r iskpat ients[3] 'However,compl ica-
tions such u, ut""ang u.rJ i**rrnotogical reactions 
have prevented its widespread
use.Thedramat icangiographicdemonstrat ionofreopeningcoronaryar ter ieshas
apparently reduced tt Jr""oU;""tions. (lncidentally, 
this iittai.tg has abolished another
t rendindenyingtheroleof-"o.onu.ythrombosis inacutemyocardia l in farct ion.) In
t h e c a s e o f i n t r a c o r o n a r y S t r e p t o k i n a s e t h e r e i s n o e x p e r i m e n t a l e v i d e n c e t h a t
reopening of coronary art"ri"s results in reestablished 
microcirculation and preven-
tion of irreversible cellular damage. The only two 
experimental studies in this case
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have, significantly enough, been performed 20 years apart [4,5] and both failed to
give quantitative comparisons of infarct size.
The present state of affairs calls for a larger influence of the results of experimen-
tal studies on clinical practice. The time between experimental demonstration of a
beneficial effect and its clinical application should be reduced, but new clinical
treatment should only be introduced after proper experimental evaluation.
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